Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013
Top Cited Papers
Open Access
- 20 September 2016
- journal article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 16 (12), 1385-1398
- https://doi.org/10.1016/s1473-3099(16)30325-5
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysisHepatology, 2013
- Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis CClinical Infectious Diseases, 2012
- Modeling causes of death: an integrated approach using CODEmPopulation Health Metrics, 2012
- Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviewsThe Lancet, 2011
- Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange programJournal of Viral Hepatitis, 2010
- Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic reviewJournal of Hepatology, 2010
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 updateHepatology International, 2008
- The effectiveness of behavioural interventions in the primary prevention of Hepatitis C amongst injecting drug users: a randomised controlled trial and lessons learnedHarm Reduction Journal, 2008
- Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug usersAddiction, 2007
- Incidence and risk factors for hepatitis C seroconversion in injecting drug users in AustraliaAddiction, 2006